-
Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential
Wednesday, October 17, 2018 - 9:41am | 412A closer look at Akorn, Inc. (NASDAQ: AKRX)'s generics business led Piper Jaffray to turn bullish on the drug manufacturer's stock. The Analyst Analyst David Amsellem upgraded Akorn from Neutral to Overweight and raised the price target from $5 to $9. The Thesis Akorn's EBITDA has...
-
Teva's New CEO Is A Positive Catalyst
Monday, September 11, 2017 - 8:35am | 451Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were trading higher by more than 11 percent early Monday morning after the company named Kare Schultz as its new CEO after a seven-month search period. Schultz brings decades of experience in the pharmaceutical industry and most...